Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Sanford and Elana Simon

A young woman sits looking and pointing a pen at a paper on a desk in a lab office. Her father leans over her shoulder looking at the same paper.

Dr. Sanford Simon and his daughter, Elana Simon, study fibrolamellar hepatocellular carcinoma, the cancer Elana was diagnosed with as a child.

Credit: Zack Veilleux / The Rockefeller University

Sanford Simon

  • The Günter Blobel Professor and Head of the Lab of Cellular Biophysics, Rockefeller University
  • President, The Fibrolamellar Registry

Elana Simon

  • Ph.D. Student in Biomedical Informatics, Stanford University
  • Director, The Fibrolamellar Registry

For Dr. Sanford Simon and daughter Elana Simon, cancer hit close to home. At 12, Elana was diagnosed with a rare liver cancer, fibrolamellar hepatocellular carcinoma (FLHCC). Surgery was the only effective treatment and resulted in Elana being cancer free. She went on to study FLHCC in her father’s lab, crowdsourcing fibrolamellar tumor samples on YouTube and discovering the genetic mutation that caused the cancer. This is now being used both for diagnosis and treatment.

FLHCC, like other childhood cancers, is quite rare, which makes it difficult to get patient information needed to study this disease. To address this, the Simons teamed up with other patients, families, and scientists to organize The Fibrolamellar Registry, a collection of health data from people with FLHCC, which allows researchers to make use of patient information across institutions and over time.  

“New technologies are making it possible for us to share our information to help identify and understand our diseases,” said Elana. “Through these, there is hope for cures that previously would have been considered miracles.”

Sign up to get stories like this and CCDI updates in your inbox

  • Posted:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Sanford and Elana Simon was originally published by the National Cancer Institute.”

Email